CN1092045C - 泡状复合物及其制备和应用方法 - Google Patents

泡状复合物及其制备和应用方法 Download PDF

Info

Publication number
CN1092045C
CN1092045C CN98810484A CN98810484A CN1092045C CN 1092045 C CN1092045 C CN 1092045C CN 98810484 A CN98810484 A CN 98810484A CN 98810484 A CN98810484 A CN 98810484A CN 1092045 C CN1092045 C CN 1092045C
Authority
CN
China
Prior art keywords
nucleic acid
composition
local anesthetic
lamellar vesicles
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98810484A
Other languages
English (en)
Chinese (zh)
Other versions
CN1277549A (zh
Inventor
R·B·西卡雷利
C·萨蒂什钱德拉
C·J·帕丘克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of CN1277549A publication Critical patent/CN1277549A/zh
Application granted granted Critical
Publication of CN1092045C publication Critical patent/CN1092045C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/905—Specially adapted for travel through blood circulatory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN98810484A 1997-04-30 1998-04-30 泡状复合物及其制备和应用方法 Expired - Fee Related CN1092045C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4512297P 1997-04-30 1997-04-30
US60/045,122 1997-04-30

Publications (2)

Publication Number Publication Date
CN1277549A CN1277549A (zh) 2000-12-20
CN1092045C true CN1092045C (zh) 2002-10-09

Family

ID=21936112

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98810484A Expired - Fee Related CN1092045C (zh) 1997-04-30 1998-04-30 泡状复合物及其制备和应用方法

Country Status (12)

Country Link
US (2) US6217900B1 (enExample)
EP (1) EP0986372B1 (enExample)
JP (1) JP2002508747A (enExample)
KR (1) KR100554344B1 (enExample)
CN (1) CN1092045C (enExample)
AT (1) ATE446372T1 (enExample)
AU (1) AU728115C (enExample)
BR (1) BR9809006B1 (enExample)
CA (1) CA2285298C (enExample)
DE (1) DE69841251D1 (enExample)
ES (1) ES2333282T3 (enExample)
WO (1) WO1998048780A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3785932B2 (ja) * 1998-05-25 2006-06-14 日本新薬株式会社 核酸含有複合体製剤の製造方法
AU776150B2 (en) * 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
EP1097993A3 (en) * 1999-11-05 2004-01-07 National Institute of Advanced Industrial Science and Technology Functional ribozyme chimeric molecules capable of sliding
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1478992A4 (en) * 2002-02-07 2007-03-21 Univ Utah Res Found METHOD FOR PRODUCING AND USING A TREATMENT PROTOCOL
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
WO2003106636A2 (en) * 2002-06-14 2003-12-24 Mirus Corporation Novel methods for the delivery of polynucleotides to cells
US20050239728A1 (en) * 2002-07-31 2005-10-27 Pachuk Catherine J Double stranded rna structures and constructs, and methods for generating and using the same
WO2004073631A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
DK2270162T3 (en) 2003-06-12 2019-01-21 Alnylam Pharmaceuticals Inc PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CA2824308A1 (en) 2004-09-24 2006-04-06 Alnylam Pharmaceuticals, Inc. Targeting opposite strand replication intermediates of single-stranded viruses by rnai
WO2006069064A2 (en) 2004-12-22 2006-06-29 Nucleonics, Inc. Conserved hbv and hcv sequences useful for gene silencing
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
DK2094086T3 (da) 2006-11-08 2013-11-25 Veritas Bio LLC Indgivelse in vivo af dobbeltstrenget rna til en målcelle
WO2009023386A2 (en) * 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
DK2427472T3 (en) 2009-05-05 2016-09-12 Miragen Therapeutics Lipophilic polynukleotidkonjugater
MA33488B1 (fr) 2009-06-08 2012-08-01 Miragen Therapeutics Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
RS55544B1 (sr) 2010-04-01 2017-05-31 Pharmanest Ab Termogelirajuće anestetičke kompozicije
CN103492569B (zh) 2010-11-05 2020-04-07 米拉根医疗公司 碱基经修饰的寡核苷酸
EP2652151A2 (en) 2010-12-15 2013-10-23 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
AU2012242761A1 (en) 2011-04-12 2013-10-31 Beth Israel Deaconess Medical Center, Inc. Micro-RNA inhibitors and their uses in disease
EP2755663A4 (en) 2011-09-13 2015-10-07 Ottawa Hospital Res Inst MicroRNA Inhibitors
EP2864482A4 (en) 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
MX364814B (es) 2013-03-15 2019-05-08 Miragen Therapeutics Inc Nucleosidos biciclicos unidos en puente.
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
WO2015074010A2 (en) 2013-11-18 2015-05-21 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
WO2016022536A2 (en) 2014-08-04 2016-02-11 MiRagen Therapeutics, Inc. Inhibitors of myh7b and uses thereof
CN107108685B (zh) 2014-09-08 2020-10-20 米拉根医疗股份有限公司 miR-29模拟物及其用途
HK1249108A1 (zh) 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
MX368314B (es) 2015-06-05 2019-09-27 Miragen Therapeutics Inc Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl).
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
US10357543B2 (en) 2015-11-16 2019-07-23 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein
WO2017222911A1 (en) 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Circular rnas and their use in immunomodulation
UY37376A (es) 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
ES2659845B1 (es) 2016-09-19 2019-01-04 Univ Valencia Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
AR113490A1 (es) 2017-12-12 2020-05-06 Amgen Inc CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
CN111918968B (zh) 2018-03-14 2023-11-24 贝斯以色列女执事医疗中心 Micro-RNA 22的抑制剂
CA3121510A1 (en) 2018-12-10 2020-06-18 Amgen Inc. Rnai constructs for inhibiting pnpla3 expression and methods of use thereof
SG11202105900UA (en) 2018-12-10 2021-07-29 Amgen Inc CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
SG11202113112WA (en) 2019-05-30 2021-12-30 Amgen Inc Rnai constructs for inhibiting scap expression and methods of use thereof
US20220340911A1 (en) 2019-08-13 2022-10-27 Amgen Inc. Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
JP7827623B2 (ja) 2019-12-09 2026-03-10 アムジエン・インコーポレーテツド ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法
WO2021234607A1 (en) 2020-05-20 2021-11-25 St. Jude Children's Research Hospital Detection of alzheimer's disease using specific biomarkers
US20230279399A1 (en) 2020-06-01 2023-09-07 Amgen Inc. Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
EP3929295A1 (en) 2020-06-26 2021-12-29 Universitat Pompeu Fabra Artificial rnas for modulating rna fragments
EP4196584A2 (en) 2020-08-13 2023-06-21 Amgen Inc. Rnai constructs and methods for inhibiting marc1 expression
KR20230104200A (ko) 2020-11-05 2023-07-07 암젠 인크 LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
US20250011779A1 (en) 2021-10-05 2025-01-09 Amgen Inc. Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds
CA3235262A1 (en) 2021-10-22 2023-04-27 Amgen Inc. Rnai constructs for inhibiting gpam expression and methods of use thereof
CA3262515A1 (en) 2022-07-25 2024-02-01 Amgen Inc. ARNI CONSTRUCTIONS AND METHODS FOR INHIBITING FAM13A EXPRESSION
EP4353823A1 (en) 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibitors of micro-rna 22
KR20250119645A (ko) 2022-12-16 2025-08-07 암젠 인크 Ttr 발현을 억제하기 위한 rnai 구성체 및 이의 사용 방법
WO2025260042A1 (en) 2024-06-14 2025-12-18 Amgen Inc. Rnai constructs and methods for inhibiting cnr1 expression
WO2026006275A2 (en) 2024-06-26 2026-01-02 Amgen Inc. Rnai constructs and methods for inhibiting expression of inhbe

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
ES2249760T3 (es) * 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y procedimientos de administracion de materias geneticas.
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ES2176360T3 (es) * 1994-12-30 2002-12-01 Chiron Corp Combinacion de vehiculos de administracion de genes.
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion

Also Published As

Publication number Publication date
KR20010020161A (ko) 2001-03-15
AU728115C (en) 2004-01-22
CN1277549A (zh) 2000-12-20
AU728115B2 (en) 2001-01-04
US6217900B1 (en) 2001-04-17
BR9809006A (pt) 2000-08-08
ES2333282T3 (es) 2010-02-18
CA2285298A1 (en) 1998-11-05
DE69841251D1 (de) 2009-12-03
KR100554344B1 (ko) 2006-02-22
WO1998048780A1 (en) 1998-11-05
EP0986372A4 (en) 2002-06-19
ATE446372T1 (de) 2009-11-15
JP2002508747A (ja) 2002-03-19
US6383512B1 (en) 2002-05-07
EP0986372A1 (en) 2000-03-22
BR9809006B1 (pt) 2010-02-09
CA2285298C (en) 2008-12-23
AU7272498A (en) 1998-11-24
EP0986372B1 (en) 2009-10-21

Similar Documents

Publication Publication Date Title
CN1277549A (zh) 泡状复合物及其制备和应用方法
CN1109046C (zh) 细胞毒t淋巴细胞应答的诱导
CN1138533C (zh) 脂质体
CN100340289C (zh) 增强核酸接种免疫应答的方法
US20190275145A1 (en) Particulate vaccine formulations
CN1088599C (zh) 包括一种抗原或包含氨基酸序列化合物的体内发生器的治疗性组合物
JP6279672B2 (ja) フルオロカーボン連結ペプチド製剤
CN1180697A (zh) 用于基因治疗的阳离子类脂
HK1039072A1 (zh) 佐剂组合物及其使用方法
CN1349402A (zh) 生物活性络合物于脂质体中囊封工艺
AU745805B2 (en) Compositions and methods for delivery of genetic material
WO2001009303A2 (en) Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
CN1893926A (zh) 包含含有药物成分的亲脂胺的稳定脂质体组合物
CN1882358A (zh) 添加烷基磷脂酰胆碱作为辅药的疫苗组合物
CN1479632A (zh) 用于将核酸导入细胞的复合物
CN1638780A (zh) 用脉冲电场进行颗粒辅助的多核苷酸免疫的方法
CN1744883A (zh) 获得蜗形结构的方法、其疫苗组合物、佐剂以及中间体
CN1414864A (zh) 粘粒dna构建体以及制备和使用该构建体的方法
TWI756948B (zh) 胜肽奈米管之製備方法、用途及其免疫組成物
CN1726183A (zh) 阳离子心磷脂类似物及其应用
CN1829535A (zh) 用于接种的sphingoid聚烷基胺缀合物
WO2017205550A1 (en) Immunogenic cochleates and methods of use
CN1720998A (zh) 猪白细胞介素－2基因抗感染制剂的制备及应用
HK40041286B (en) Lipid nanoparticles
HK1008226B (en) Induction of cytotoxic t-lymphocyte responses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20021009

Termination date: 20120430